{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:32:30Z","timestamp":1790343150315,"version":"4.1.0"},"reference-count":242,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease and is closely associated with metabolic diseases such as obesity, type 2 diabetes mellitus (T2DM), and metabolic syndrome. However, effective treatment strategies for NAFLD are still lacking. In recent years, progress has been made in understanding the pathogenesis of NAFLD, identifying multiple therapeutic targets and providing new directions for drug development. This review summarizes the recent advances in the treatment of NAFLD, focusing on the mechanisms of action of natural products, small-synthetic-molecule drugs, and combination therapy strategies. This review aims to provide new insights and strategies in treating NAFLD.<\/jats:p>","DOI":"10.3390\/biom15010140","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T03:33:02Z","timestamp":1737084782000},"page":"140","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Drug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs"],"prefix":"10.3390","volume":"15","author":[{"given":"Xing","family":"Wan","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Dalian Medical University, Dalian 116012, China"},{"name":"Institute of Integrated Traditional Chinese and Western Medicine, Dalian Medical University, Dalian 116051, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyuan","family":"Ma","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Liaoning University of Traditional Chinese Medicine, Shenyang 110033, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Bai","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Dalian Medical University, Dalian 116012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyang","family":"Hu","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College, Liaoning University of Traditional Chinese Medicine, Shenyang 110033, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanna","family":"Ma","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Liaoning University of Traditional Chinese Medicine, Shenyang 110033, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjian","family":"Zhao","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Dalian Medical University, Dalian 116012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifeng","family":"Liu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Dalian Medical University, Dalian 116012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7976-4959","authenticated-orcid":false,"given":"Zhijun","family":"Duan","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Dalian Medical University, Dalian 116012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Nassir, F. (2022). NAFLD: Mechanisms, Treatments, and Biomarkers. Biomolecules, 12.","DOI":"10.3390\/biom12060824"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive Assessment of Liver Disease in Patients with Nonalcoholic Fatty Liver Disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metab. Clin. Exp."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.21037\/hbsn.2018.11.06","article-title":"Non-alcoholic fatty liver disease (NAFLD) and the quest for effective treatments","volume":"8","author":"Thanapirom","year":"2019","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Le Garf, S., N\u00e8gre, V., Anty, R., and Gual, P. (2021). Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem. Biomedicines, 9.","DOI":"10.3390\/biomedicines9121915"},{"key":"ref_8","first-page":"e16220","article-title":"The Role of Exercise in Steatotic Liver Diseases: An Updated Perspective","volume":"45","author":"Fares","year":"2025","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Liu, Y., Fan, Y., Liu, J., Liu, X., Li, X., and Hu, J. (2024). Application and mechanism of Chinese herb medicine in the treatment of non-alcoholic fatty liver disease. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1499602"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.3748\/wjg.v30.i48.5205","article-title":"GLP-1, GIP\/GLP-1, and GCGR\/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis","volume":"30","author":"Singh","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"ref_11","first-page":"724","article-title":"Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies","volume":"22","author":"Chen","year":"2024","journal-title":"Chin. J. Nat. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Tarantino, G., Balsano, C., Santini, S.J., Brienza, G., Clemente, I., Cosimini, B., and Sinatti, G. (2021). It Is High Time Physicians Thought of Natural Products for Alleviating NAFLD. Is There Sufficient Evidence to Use Them?. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222413424"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Chen, Q., Wang, T., Li, J., Wang, S., Qiu, F., Yu, H., Zhang, Y., and Wang, T. (2017). Effects of Natural Products on Fructose-Induced Nonalcoholic Fatty Liver Disease (NAFLD). Nutrients, 9.","DOI":"10.3390\/nu9020096"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Guo, X., Yin, X., Liu, Z., and Wang, J. (2022). Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232415489"},{"key":"ref_15","first-page":"37","article-title":"Pimpinella anisum L. fruit: Chemical composition and effect on rat model of nonalcoholic fatty liver disease","volume":"22","author":"Asadollahpoor","year":"2017","journal-title":"J. Res. Med. Sci. Off. J. Isfahan Univ. Med. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Yao, W., Fan, M., Qian, H., Li, Y., and Wang, L. (2024). Quinoa Polyphenol Extract Alleviates Non-Alcoholic Fatty Liver Disease via Inhibiting Lipid Accumulation, Inflammation and Oxidative Stress. Nutrients, 16.","DOI":"10.3390\/nu16142276"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"16067","DOI":"10.1021\/acs.jafc.3c02337","article-title":"Green Pea (Pisum sativum L.) Hull Polyphenol Extract Alleviates NAFLD Through VB6\/TLR4\/NF-\u03baB and PPAR Pathways","volume":"71","author":"Guo","year":"2023","journal-title":"J. Agric. Food Chem."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"He, Y., Wang, H., Lin, S., Chen, T., Chang, D., Sun, Y., Wang, C., Liu, Y., Lu, Y., and Song, J. (2023). Advanced effect of curcumin and resveratrol on mitigating hepatic steatosis in metabolic associated fatty liver disease via the PI3K\/AKT\/mTOR and HIF-1\/VEGF cascade. Biomed. Pharmacother., 165.","DOI":"10.1016\/j.biopha.2023.115279"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"640","DOI":"10.4093\/dmj.2020.0115","article-title":"Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming","volume":"44","author":"Jeong","year":"2020","journal-title":"Diabetes Metab. J."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Li, L., Qin, Y., Xin, X., Wang, S., Liu, Z., and Feng, X. (2023). The great potential of flavonoids as candidate drugs for NAFLD. Biomed. Pharmacother., 164.","DOI":"10.1016\/j.biopha.2023.114991"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.2174\/0929867322666150805094940","article-title":"Flavonoids and Related Compounds in Non-Alcoholic Fatty Liver Disease Therapy","volume":"22","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"10186","DOI":"10.1039\/D2FO01682F","article-title":"Nobiletin mitigates NAFLD via lipophagy and inflammation","volume":"13","author":"Yang","year":"2022","journal-title":"Food Funct."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"20105","DOI":"10.1021\/acs.jafc.3c06498","article-title":"Nobiletin Ameliorates Hepatic Lipid Deposition, Oxidative Stress, and Inflammation by Mechanisms That Involve the Nrf2\/NF-\u03baB Axis in Nonalcoholic Fatty Liver Disease","volume":"71","author":"Fan","year":"2023","journal-title":"J. Agric. Food Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.1021\/acs.jafc.2c08637","article-title":"Nobiletin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Gut Microbiota and Myristoleic Acid Metabolism","volume":"71","author":"Li","year":"2023","journal-title":"J. Agric. Food Chem."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Bunbupha, S., Pakdeechote, P., Maneesai, P., and Prasarttong, P. (2021). Nobiletin alleviates high-fat diet-induced nonalcoholic fatty liver disease by modulating AdipoR1 and gp91(phox) expression in rats. J. Nutr. Biochem., 87.","DOI":"10.1016\/j.jnutbio.2020.108526"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"G387","DOI":"10.1152\/ajpgi.00130.2022","article-title":"The biological clock enhancer nobiletin ameliorates steatosis in genetically obese mice by restoring aberrant hepatic circadian rhythm","volume":"323","author":"Larion","year":"2022","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ke, Z., Fan, C., Li, J., Wang, L., Li, H., Tian, W., and Yu, Q. (2023). Nobiletin Intake Attenuates Hepatic Lipid Profiling and Oxidative Stress in HFD-Induced Nonalcoholic-Fatty-Liver-Disease Mice. Molecules, 28.","DOI":"10.3390\/molecules28062570"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Gnoni, A., Di Chiara Stanca, B., Giannotti, L., Gnoni, G.V., Siculella, L., and Damiano, F. (2022). Quercetin Reduces Lipid Accumulation in a Cell Model of NAFLD by Inhibiting De Novo Fatty Acid Synthesis through the Acetyl-CoA Carboxylase 1\/AMPK\/PP2A Axis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031044"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ajcnut.2024.07.013","article-title":"Quercetin intervention reduced hepatic fat deposition in patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled crossover clinical trial","volume":"120","author":"Li","year":"2024","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Cao, P., Wang, Y., Zhang, C., Sullivan, M.A., Chen, W., Jing, X., Yu, H., Li, F., Wang, Q., and Zhou, Z. (2023). Quercetin ameliorates nonalcoholic fatty liver disease (NAFLD) via the promotion of AMPK-mediated hepatic mitophagy. J. Nutr. Biochem., 120.","DOI":"10.1016\/j.jnutbio.2023.109414"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1002\/ptr.6486","article-title":"Quercetin improves nonalcoholic fatty liver by ameliorating inflammation, oxidative stress, and lipid metabolism in db\/db mice","volume":"33","author":"Yang","year":"2019","journal-title":"Phytother. Res. PTR"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Jiang, J.J., Zhang, G.F., Zheng, J.Y., Sun, J.H., and Ding, S.B. (2022). Targeting Mitochondrial ROS-Mediated Ferroptosis by Quercetin Alleviates High-Fat Diet-Induced Hepatic Lipotoxicity. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.876550"},{"key":"ref_33","first-page":"154703","article-title":"Targeting mTOR\/YY1 signaling pathway by quercetin through CYP7A1-mediated cholesterol-to-bile acids conversion alleviated type 2 diabetes mellitus induced hepatic lipid accumulation","volume":"113","author":"Yang","year":"2023","journal-title":"Phytomedicine Int. J. Phytother. Phytopharm."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/biof.1724","article-title":"Quercetin prevents cadmium chloride-induced hepatic steatosis and fibrosis by downregulating the transcription of miR-21","volume":"47","author":"Alshammari","year":"2021","journal-title":"BioFactors"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/advances\/nmaa106","article-title":"A Comprehensive Systematic Review of the Effects of Naringenin, a Citrus-Derived Flavonoid, on Risk Factors for Nonalcoholic Fatty Liver Disease","volume":"12","author":"Naeini","year":"2021","journal-title":"Adv. Nutr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MEG.0000000000002323","article-title":"Effects of naringenin supplementation on cardiovascular risk factors in overweight\/obese patients with nonalcoholic fatty liver disease: A pilot double-blind, placebo-controlled, randomized clinical trial","volume":"34","author":"Naeini","year":"2022","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Yang, Y., Wu, Y., Zou, J., Wang, Y.H., Xu, M.X., Huang, W., Yu, D.J., Zhang, L., Zhang, Y.Y., and Sun, X.D. (2021). Naringenin Attenuates Non-Alcoholic Fatty Liver Disease by Enhancing Energy Expenditure and Regulating Autophagy via AMPK. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.687095"},{"key":"ref_38","first-page":"153412","article-title":"Naringenin alleviates nonalcoholic steatohepatitis in middle-aged Apoe(\u2212\/\u2212)mice: Role of SIRT1","volume":"81","author":"Hua","year":"2021","journal-title":"Phytomedicine Int. J. Phytother. Phytopharm."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Shon, J.C., Kim, W.C., Ryu, R., Wu, Z., Seo, J.S., Choi, M.S., and Liu, K.H. (2020). Plasma Lipidomics Reveals Insights into Anti-Obesity Effect of Chrysanthemum morifolium Ramat Leaves and Its Constituent Luteolin in High-Fat Diet-Induced Dyslipidemic Mice. Nutrients, 12.","DOI":"10.3390\/nu12102973"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3177\/jnsv.69.259","article-title":"Luteolin Ameliorates Hepatic Steatosis and Enhances Mitochondrial Biogenesis via AMPK\/PGC-1\u03b1 Pathway in Western Diet-Fed Mice","volume":"69","author":"Wang","year":"2023","journal-title":"J. Nutr. Sci. Vitaminol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3946320221137435","DOI":"10.1177\/03946320221137435","article-title":"Luteolin loaded on zinc oxide nanoparticles ameliorates non-alcoholic fatty liver disease associated with insulin resistance in diabetic rats via regulation of PI3K\/AKT\/FoxO1 pathway","volume":"36","author":"Ahmed","year":"2022","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Liu, X., Sun, R., Li, Z., Xiao, R., Lv, P., Sun, X., Olson, M.A., and Gong, Y. (2021). Luteolin alleviates non-alcoholic fatty liver disease in rats via restoration of intestinal mucosal barrier damage and microbiota imbalance involving in gut-liver axis. Arch. Biochem. Biophys., 711.","DOI":"10.1016\/j.abb.2021.109019"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Liu, Y., Shi, X., Tian, Y., Zhai, S., Liu, Y., Xiong, Z., and Chu, S. (2023). An insight into novel therapeutic potentials of taxifolin. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1173855"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Wei, H., Zhao, T., Liu, X., Ding, Q., Yang, J., Bi, X., Cheng, Z., Ding, C., and Liu, W. (2024). Mechanism of Action of Dihydroquercetin in the Prevention and Therapy of Experimental Liver Injury. Molecules, 29.","DOI":"10.3390\/molecules29153537"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Inoue, T., Fu, B., Nishio, M., Tanaka, M., Kato, H., Tanaka, M., Itoh, M., Yamakage, H., Ochi, K., and Ito, A. (2023). Novel Therapeutic Potentials of Taxifolin for Obesity-Induced Hepatic Steatosis, Fibrogenesis, and Tumorigenesis. Nutrients, 15.","DOI":"10.3390\/nu15020350"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1039\/D0FO02653K","article-title":"Taxifolin ameliorate high-fat-diet feeding plus acute ethanol binge-induced steatohepatitis through inhibiting inflammatory caspase-1-dependent pyroptosis","volume":"12","author":"Zhan","year":"2021","journal-title":"Food Funct."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Wadhwa, K., Pahwa, R., Kumar, M., Kumar, S., Sharma, P.C., Singh, G., Verma, R., Mittal, V., Singh, I., and Kaushik, D. (2022). Mechanistic Insights into the Pharmacological Significance of Silymarin. Molecules, 27.","DOI":"10.3390\/molecules27165327"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Bijak, M. (2017). Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.)-Chemistry, Bioavailability, and Metabolism. Molecules, 22.","DOI":"10.3390\/molecules22111942"},{"key":"ref_49","first-page":"401","article-title":"Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor \u03b1","volume":"19","author":"Cui","year":"2021","journal-title":"Chin. J. Nat. Med."},{"key":"ref_50","first-page":"1940","article-title":"A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis","volume":"15","author":"Mahadeva","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Wang, X., Jin, Y., Di, C., Zeng, Y., Zhou, Y., Chen, Y., Pan, Z., Li, Z., and Ling, W. (2024). Supplementation of Silymarin Alone or in Combination with Salvianolic Acids B and Puerarin Regulates Gut Microbiota and Its Metabolism to Improve High-Fat Diet-Induced NAFLD in Mice. Nutrients, 16.","DOI":"10.3390\/nu16081169"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Choi, J., Choi, H., and Chung, J. (2023). Icariin Supplementation Suppresses the Markers of Ferroptosis and Attenuates the Progression of Nonalcoholic Steatohepatitis in Mice Fed a Methionine Choline-Deficient Diet. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241512510"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"175378","DOI":"10.1016\/j.ejphar.2022.175378","article-title":"Icaritin, a metabolite of Icarrin, Alleviates non-alcoholic fatty liver disease via inhibition of lipogenesis and ER stress","volume":"937","author":"Yu","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Hai, Y., Zuo, L., Wang, M., Zhang, R., Wang, M., Ren, L., Yang, C., and Wang, J. (2023). Icariin Alleviates Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome by Improving Liver Fatty Acid Oxidation and Inhibiting Lipid Accumulation. Molecules, 28.","DOI":"10.3390\/molecules28020517"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Zhao, H., and Tian, H. (2024). Icariin alleviates high-fat diet-induced nonalcoholic fatty liver disease via up-regulating miR-206 to mediate NF-\u03baB and MAPK pathways. J. Biochem. Mol. Toxicol., 38.","DOI":"10.1002\/jbt.23566"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1134\/S0006297921110055","article-title":"AMPK\/PGC-1\u03b1\/GLUT4-Mediated Effect of Icariin on Hyperlipidemia-Induced Non-Alcoholic Fatty Liver Disease and Lipid Metabolism Disorder in Mice","volume":"86","author":"Lin","year":"2021","journal-title":"Biochem. Biokhimiia"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e70000","DOI":"10.1111\/1440-1681.70000","article-title":"Caffeic acid phenethyl ester ameliorates colistin-induced nephrotoxicity in rats via modulation of FOXO1\/Nrf2\/Sirt1 axis","volume":"51","author":"Nasrullah","year":"2024","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s10529-021-03097-y","article-title":"Characterization of substrate specificity and inhibitory mechanism of bile salt hydrolase from Lactobacillus reuteri CRL 1098 using molecular docking analysis","volume":"43","author":"Ledesma","year":"2021","journal-title":"Biotechnol. Lett."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41401-022-00921-7","article-title":"Caffeic acid phenethyl ester suppresses intestinal FXR signaling and ameliorates nonalcoholic fatty liver disease by inhibiting bacterial bile salt hydrolase activity","volume":"44","author":"Zhong","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e1700701","DOI":"10.1002\/mnfr.201700701","article-title":"Caffeic Acid Phenethyl Ester Improves Metabolic Syndrome by Activating PPAR-\u03b3 and Inducing Adipose Tissue Remodeling in Diet-Induced Obese Mice","volume":"62","author":"Kim","year":"2018","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Jiang, W., Li, X., Dong, S., and Zhou, W. (2021). Betulinic acid in the treatment of tumour diseases: Application and research progress. Biomed. Pharmacother., 142.","DOI":"10.1016\/j.biopha.2021.111990"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/bph.14570","article-title":"Betulinic acid alleviates endoplasmic reticulum stress-mediated nonalcoholic fatty liver disease through activation of farnesoid X receptors in mice","volume":"176","author":"Gu","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.bcp.2013.02.007","article-title":"Betulinic acid alleviates non-alcoholic fatty liver by inhibiting SREBP1 activity via the AMPK-mTOR-SREBP signaling pathway","volume":"85","author":"Quan","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"ref_64","first-page":"13033","article-title":"Betulinic acid improves nonalcoholic fatty liver disease through YY1\/FAS signaling pathway","volume":"34","author":"Mu","year":"2020","journal-title":"FASEB J. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Nguyen, H.N., Ullevig, S.L., Short, J.D., Wang, L., Ahn, Y.J., and Asmis, R. (2021). Ursolic Acid and Related Analogues: Triterpenoids with Broad Health Benefits. Antioxidants, 10.","DOI":"10.3390\/antiox10081161"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"11647","DOI":"10.1021\/acs.jafc.8b04116","article-title":"Ursolic Acid, a Novel Liver X Receptor \u03b1 (LXR\u03b1) Antagonist Inhibiting Ligand-Induced Nonalcoholic Fatty Liver and Drug-Induced Lipogenesis","volume":"66","author":"Lin","year":"2018","journal-title":"J. Agric. Food Chem."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Li, S., Liao, X., Meng, F., Wang, Y., Sun, Z., Guo, F., Li, X., Meng, M., Li, Y., and Sun, C. (2014). Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0086724"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1972746","DOI":"10.1080\/19490976.2021.1972746","article-title":"Ursolic acid reverses liver fibrosis by inhibiting NOX4\/NLRP3 inflammasome pathways and bacterial dysbiosis","volume":"13","author":"Nie","year":"2021","journal-title":"Gut Microbes"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Zheng, Y., Huang, C., Zhao, L., Chen, Y., and Liu, F. (2021). Regulation of decorin by ursolic acid protects against non-alcoholic steatohepatitis. Biomed. Pharmacother., 143.","DOI":"10.1016\/j.biopha.2021.112166"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"121110","DOI":"10.1016\/j.lfs.2022.121110","article-title":"Modulation of gut microbiota by glycyrrhizic acid may contribute to its anti-NAFLD effect in rats fed a high-fat diet","volume":"310","author":"Wang","year":"2022","journal-title":"Life Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1080\/13880209.2022.2126503","article-title":"Gypenosides counteract hepatic steatosis and intestinal barrier injury in rats with metabolic associated fatty liver disease by modulating the adenosine monophosphate activated protein kinase and Toll-like receptor 4\/nuclear factor kappa B pathways","volume":"60","author":"Shen","year":"2022","journal-title":"Pharm. Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e15225","DOI":"10.7717\/peerj.15225","article-title":"Gypenosides ameliorate high-fat diet-induced nonalcoholic fatty liver disease in mice by regulating lipid metabolism","volume":"11","author":"Zhou","year":"2023","journal-title":"PeerJ"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/kjm2.12795","article-title":"Gypenoside XIII regulates lipid metabolism in HepG2 hepatocytes and ameliorates nonalcoholic steatohepatitis in mice","volume":"40","author":"Cheng","year":"2024","journal-title":"Kaohsiung J. Med. Sci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1039\/D3FO05484E","article-title":"Ginsenoside\u2014A promising natural active ingredient with steroidal hormone activity","volume":"15","author":"Li","year":"2024","journal-title":"Food Funct."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jgr.2023.10.001","article-title":"Ginsenoside F2 Restrains Hepatic Steatosis and Inflammation by Altering the Binding Affinity of Liver X Receptor Coregulators","volume":"48","author":"Kim","year":"2024","journal-title":"J. Ginseng Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"10878","DOI":"10.1021\/acsomega.0c00529","article-title":"Ginsenoside Rg1 Regulates Liver Lipid Factor Metabolism in NAFLD Model Rats","volume":"5","author":"Hou","year":"2020","journal-title":"ACS Omega"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"118986","DOI":"10.1016\/j.lfs.2020.118986","article-title":"Transcriptome analysis reveals the efficacy of ginsenoside-Rg1 in the treatment of nonalcoholic fatty liver disease","volume":"267","author":"Gu","year":"2021","journal-title":"Life Sci."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Yang, S., Duan, Z., Zhang, S., Fan, C., Zhu, C., Fu, R., Ma, X., and Fan, D. (2023). Ginsenoside Rh4 Improves Hepatic Lipid Metabolism and Inflammation in a Model of NAFLD by Targeting the Gut Liver Axis and Modulating the FXR Signaling Pathway. Foods, 12.","DOI":"10.3390\/foods12132492"},{"key":"ref_79","first-page":"155287","article-title":"Ginsenoside Rg5 inhibits lipid accumulation and hepatocyte apoptosis via the Notch1 signaling pathway in NASH mice","volume":"124","author":"Li","year":"2024","journal-title":"Phytomedicine Int. J. Phytother. Phytopharm."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jgr.2020.07.005","article-title":"Ginsenosides Rc, as a novel SIRT6 activator, protects mice against high fat diet induced NAFLD","volume":"47","author":"Yang","year":"2023","journal-title":"J. Ginseng Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"9370","DOI":"10.1021\/acs.jafc.3c00789","article-title":"Ginsenoside Rk3 Regulates Nonalcoholic Steatohepatitis by Modulation of Intestinal Flora and the PI3K\/AKT Signaling Pathway in C57BL\/6 Mice","volume":"71","author":"Guo","year":"2023","journal-title":"J. Agric. Food Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"176737","DOI":"10.1016\/j.ejphar.2024.176737","article-title":"Diosgenin attenuates nonalcoholic hepatic steatosis through the hepatic SIRT1\/PGC-1\u03b1 pathway","volume":"977","author":"Meng","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"ref_83","first-page":"154661","article-title":"Diosgenin attenuates non-alcoholic fatty liver disease in type 2 diabetes through regulating SIRT6-related fatty acid uptake","volume":"111","author":"Nie","year":"2023","journal-title":"Phytomedicine Int. J. Phytother. Phytopharm."},{"key":"ref_84","first-page":"155299","article-title":"Diosgenin as a substitute for cholesterol alleviates NAFLD by affecting CYP7A1 and NPC1L1-related pathway","volume":"125","author":"Yan","year":"2024","journal-title":"Phytomedicine Int. J. Phytother. Phytopharm."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"106621","DOI":"10.1016\/j.phrs.2022.106621","article-title":"Diosgenin alleviates nonalcoholic steatohepatitis through affecting liver-gut circulation","volume":"187","author":"Yan","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"175808","DOI":"10.1016\/j.ejphar.2023.175808","article-title":"Diosgenin attenuates nonalcoholic hepatic steatosis through the hepatic FXR-SHP-SREBP1C\/PPAR\u03b1\/CD36 pathway","volume":"952","author":"Chen","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"112581","DOI":"10.1016\/j.intimp.2024.112581","article-title":"Diosgenin attenuates metabolic-associated fatty liver disease through the hepatic NLRP3 inflammasome-dependent signaling pathway","volume":"138","author":"Yu","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e2300561","DOI":"10.1002\/mnfr.202300561","article-title":"Gut Microbiota Plays Essential Roles in Soyasaponin\u2019s Preventive Bioactivities against Steatohepatitis in the Methionine and Choline Deficient (MCD) Diet-Induced Non-Alcoholic Steatohepatitis (NASH) Mice","volume":"68","author":"Su","year":"2024","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"James, A., Wang, K., and Wang, Y. (2023). Therapeutic Activity of Green Tea Epigallocatechin-3-Gallate on Metabolic Diseases and Non-Alcoholic Fatty Liver Diseases: The Current Updates. Nutrients, 15.","DOI":"10.3390\/nu15133022"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.clnu.2024.06.018","article-title":"Epigallocatechin gallate alleviates non-alcoholic fatty liver disease through the inhibition of the expression and activity of Dipeptide kinase 4","volume":"43","author":"Yang","year":"2024","journal-title":"Clin. Nutr."},{"key":"ref_91","first-page":"9067","article-title":"Tea Polyphenol Epigallocatechin Gallate Protects Against Nonalcoholic Fatty Liver Disease and Associated Endotoxemia in Rats via Modulating Gut Microbiota Dysbiosis and Alleviating Intestinal Barrier Dysfunction and Related Inflammation","volume":"72","author":"Zuo","year":"2024","journal-title":"J. Agric. Food Chem."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Ding, S.B., Chu, X.L., Jin, Y.X., Jiang, J.J., Zhao, X., and Yu, M. (2023). Epigallocatechin gallate alleviates high-fat diet-induced hepatic lipotoxicity by targeting mitochondrial ROS-mediated ferroptosis. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1148814"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e2101033","DOI":"10.1002\/mnfr.202101033","article-title":"Curcumin Mitigates TNF\u03b1-Induced Caco-2 Cell Monolayer Permeabilization Through Modulation of NF-\u03baB, ERK1\/2, and JNK Pathways","volume":"66","author":"Iglesias","year":"2022","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_94","first-page":"134","article-title":"Effect of curcumin on intestinal mucosal mechanical barrier in rats with non-alcoholic fatty liver disease","volume":"25","author":"Hou","year":"2017","journal-title":"Zhonghua Gan Zang Bing Za Zhi Zhonghua Ganzangbing Zazhi Chin. J. Hepatol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Zeng, Y., Luo, Y., Wang, L., Zhang, K., Peng, J., and Fan, G. (2023). Therapeutic Effect of Curcumin on Metabolic Diseases: Evidence from Clinical Studies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043323"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1039\/D1FO03752H","article-title":"Curcumin alleviates hepatic steatosis by improving mitochondrial function in postnatal overfed rats and fatty L02 cells through the SIRT3 pathway","volume":"13","author":"Du","year":"2022","journal-title":"Food Funct."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"500","DOI":"10.4093\/dmj.2022.0110","article-title":"Beneficial Effects of a Curcumin Derivative and Transforming Growth Factor-\u03b2 Receptor I Inhibitor Combination on Nonalcoholic Steatohepatitis","volume":"47","author":"Ha","year":"2023","journal-title":"Diabetes Metab. J."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13020-021-00470-x","article-title":"Herbal therapy for ameliorating nonalcoholic fatty liver disease via rebuilding the intestinal microecology","volume":"16","author":"Yang","year":"2021","journal-title":"Chin. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.fct.2012.10.026","article-title":"Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type I gene expressions in rats","volume":"52","author":"Xin","year":"2013","journal-title":"Food Chem. Toxicol. Int. J. Publ. Br. Ind. Biol. Res. Assoc."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"He, X., Li, Y., Deng, X., Xiao, X., and Zeng, J. (2023). Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: Preclinical and clinical meta-analyses. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1230783"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Zhen, Q., Liang, Q., Wang, H., Zheng, Y., Lu, Z., Bian, C., Zhao, X., and Guo, X. (2023). Theabrownin ameliorates liver inflammation, oxidative stress, and fibrosis in MCD diet-fed C57BL\/6J mice. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1118925"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Chen, Y., Xie, C., Lei, Y., Ye, D., Wang, L., Xiong, F., Wu, H., He, Q., Zhou, H., and Li, L. (2024). Theabrownin from Qingzhuan tea prevents high-fat diet-induced MASLD via regulating intestinal microbiota. Biomed. Pharmacother., 174.","DOI":"10.1016\/j.biopha.2024.116582"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jare.2023.01.008","article-title":"Theabrownin inhibits obesity and non-alcoholic fatty liver disease in mice via serotonin-related signaling pathways and gut-liver axis","volume":"52","author":"Li","year":"2023","journal-title":"J. Adv. Res."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Wang, J., Zheng, D., Huang, F., Zhao, A., Kuang, J., Ren, Z., Chen, T., Lei, J., Lin, J., and Wang, X. (2022). Theabrownin and Poria cocos Polysaccharide Improve Lipid Metabolism via Modulation of Bile Acid and Fatty Acid Metabolism. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.875549"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Koperska, A., Weso\u0142ek, A., Moszak, M., and Szuli\u0144ska, M. (2022). Berberine in Non-Alcoholic Fatty Liver Disease-A Review. Nutrients, 14.","DOI":"10.3390\/nu14173459"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Xu, X., Yi, H., Wu, J., Kuang, T., Zhang, J., Li, Q., Du, H., Xu, T., Jiang, G., and Fan, G. (2021). Therapeutic effect of berberine on metabolic diseases: Both pharmacological data and clinical evidence. Biomed. Pharmacother., 133.","DOI":"10.1016\/j.biopha.2020.110984"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.7150\/ijbs.54604","article-title":"Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver","volume":"17","author":"Yu","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Wang, Y., Zhou, X., Zhao, D., Wang, X., Gurley, E.C., Liu, R., Li, X., Hylemon, P.B., Chen, W., and Zhou, H. (2020). Berberine inhibits free fatty acid and LPS-induced inflammation via modulating ER stress response in macrophages and hepatocytes. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0232630"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Yan, H.M., Xia, M.F., Wang, Y., Chang, X.X., Yao, X.Z., Rao, S.X., Zeng, M.S., Tu, Y.F., Feng, R., and Jia, W.P. (2015). Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0134172"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Liu, D., Ye, J., Yan, Y., Chen, Y., Wang, H., Wang, M., Feng, Y., Li, R., Xu, X., and Jiang, Y. (2023). Ramulus mori (Sangzhi) alkaloids regulates gut microbiota disorder and its metabolism profiles in obese mice induced by a high-fat diet. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1166635"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Zhang, M., Guo, C., Li, Z., Cai, X., Wen, X., Lv, F., Lin, C., and Ji, L. (2024). Mulberry Twig Alkaloids Improved the Progression of Metabolic-Associated Fatty Liver Disease in High-Fat Diet-Induced Obese Mice by Regulating the PGC1\u03b1\/PPAR\u03b1 and KEAP1\/NRF2 Pathways. Pharmaceuticals, 17.","DOI":"10.3390\/ph17101287"},{"key":"ref_112","first-page":"154798","article-title":"Neferine ameliorates nonalcoholic steatohepatitis through regulating AMPK pathway","volume":"114","author":"Wang","year":"2023","journal-title":"Phytomedicine Int. J. Phytother. Phytopharm."},{"key":"ref_113","first-page":"155919","article-title":"Yellow tea polysaccharides protect against non-alcoholic fatty liver disease via regulation of gut microbiota and bile acid metabolism in mice","volume":"133","author":"Huang","year":"2024","journal-title":"Phytomedicine Int. J. Phytother. Phytopharm."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"7230","DOI":"10.1021\/acs.jafc.4c00616","article-title":"Large Yellow Tea Polysaccharide Alleviates HFD-Induced Intestinal Homeostasis Dysbiosis via Modulating Gut Barrier Integrity, Immune Responses, and the Gut Microbiome","volume":"72","author":"Ma","year":"2024","journal-title":"J. Agric. Food Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"9337","DOI":"10.1039\/D3FO01691A","article-title":"Large yellow tea polysaccharides ameliorate obesity-associated metabolic syndrome by promoting M2 polarization of adipose tissue macrophages","volume":"14","author":"Wang","year":"2023","journal-title":"Food Funct."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"12565","DOI":"10.1021\/acs.jafc.2c05593","article-title":"Structural Characterization and Macrophage Polarization-Modulating Activity of a Novel Polysaccharide from Large Yellow Tea","volume":"70","author":"Wang","year":"2022","journal-title":"J. Agric. Food Chem."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"122139","DOI":"10.1016\/j.carbpol.2024.122139","article-title":"RG-I pectin-like polysaccharide from Rosa chinensis inhibits inflammation and fibrosis associated to HMGB1\/TLR4\/NF-\u03baB signaling pathway to improve non-alcoholic steatohepatitis","volume":"337","author":"Jing","year":"2024","journal-title":"Carbohydr. Polym."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.7150\/ijbs.59918","article-title":"The Impact of TRPV1 on Cancer Pathogenesis and Therapy: A Systematic Review","volume":"17","author":"Li","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/oby.2009.301","article-title":"Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet","volume":"18","author":"Kang","year":"2010","journal-title":"Obesity"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/19768354.2020.1810771","article-title":"Capsaicin suppresses liver fat accumulation in high-fat diet-induced NAFLD mice","volume":"24","author":"Shin","year":"2020","journal-title":"Anim. Cells Syst."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Winarto, J., Song, D.G., and Pan, C.H. (2023). The Role of Fucoxanthin in Non-Alcoholic Fatty Liver Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24098203"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"9854","DOI":"10.1021\/acsami.3c18029","article-title":"Orally Deliverable Sequence-Targeted Fucoxanthin-Loaded Biomimetic Extracellular Vesicles for Alleviation of Nonalcoholic Fatty Liver Disease","volume":"16","author":"Wu","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Ye, J., Zheng, J., Tian, X., Xu, B., Yuan, F., Wang, B., Yang, Z., and Huang, F. (2022). Fucoxanthin Attenuates Free Fatty Acid-Induced Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism\/Oxidative Stress\/Inflammation via the AMPK\/Nrf2\/TLR4 Signaling Pathway. Mar. Drugs, 20.","DOI":"10.3390\/md20040225"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e33631","DOI":"10.1016\/j.heliyon.2024.e33631","article-title":"Advances in the mechanism of emodin-induced hepatotoxicity","volume":"10","author":"Wang","year":"2024","journal-title":"Heliyon"},{"key":"ref_125","first-page":"2362","article-title":"Prepared Radix Polygoni Multiflori and emodin alleviate lipid droplet accumulation in nonalcoholic fatty liver disease through MAPK signaling pathway inhibition","volume":"16","author":"Huang","year":"2024","journal-title":"Aging"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"114340","DOI":"10.1016\/j.jep.2021.114340","article-title":"Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway","volume":"279","author":"Shen","year":"2021","journal-title":"J. Ethnopharmacol."},{"key":"ref_127","first-page":"E105","article-title":"Emodin ameliorates hepatic steatosis through endoplasmic reticulum-stress sterol regulatory element-binding protein 1c pathway in liquid fructose-feeding rats","volume":"46","author":"Li","year":"2016","journal-title":"Hepatol. Res. Off. J. Jpn. Soc. Hepatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/hepr.12788","article-title":"Emodin alleviates hepatic steatosis by inhibiting sterol regulatory element binding protein 1 activity by way of the calcium\/calmodulin-dependent kinase kinase-AMP-activated protein kinase-mechanistic target of rapamycin-p70 ribosomal S6 kinase signaling pathway","volume":"47","author":"Wang","year":"2017","journal-title":"Hepatol. Res. Off. J. Jpn. Soc. Hepatol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Frasinariu, O., Serban, R., Trandafir, L.M., Miron, I., Starcea, M., Vasiliu, I., Alisi, A., and Temneanu, O.R. (2022). The Role of Phytosterols in Nonalcoholic Fatty Liver Disease. Nutrients, 14.","DOI":"10.3390\/nu14112187"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Abo-Zaid, O.A., Moawed, F.S., Ismail, E.S., and Farrag, M.A. (2023). \u03b2-sitosterol attenuates high- fat diet-induced hepatic steatosis in rats by modulating lipid metabolism, inflammation and ER stress pathway. BMC Pharmacol. Toxicol., 24.","DOI":"10.1186\/s40360-023-00671-0"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Pi, D., Liang, Z., Pan, J., Zhen, J., Zheng, C., Fan, W., Song, Q., Pan, M., Yang, Q., and Zhang, Y. (2024). Tanshinone IIA Inhibits the Endoplasmic Reticulum Stress-Induced Unfolded Protein Response by Activating the PPAR\u03b1\/FGF21 Axis to Ameliorate Nonalcoholic Steatohepatitis. Antioxidants, 13.","DOI":"10.3390\/antiox13091026"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/fcp.12510","article-title":"Tanshinone IIA reduces palmitate-induced apoptosis via inhibition of endoplasmic reticulum stress in HepG2 liver cells","volume":"34","author":"Wang","year":"2020","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"118662","DOI":"10.1016\/j.jep.2024.118662","article-title":"TFEB activator tanshinone IIA and derivatives derived from Salvia miltiorrhiza Bge. Attenuate hepatic steatosis and insulin resistance","volume":"335","author":"Zheng","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3892\/etm.2022.11413","article-title":"Tanshinone IIA regulates the TGF-\u03b21\/Smad signaling pathway to ameliorate non-alcoholic steatohepatitis-related fibrosis","volume":"24","author":"Xu","year":"2022","journal-title":"Exp. Ther. Med."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Gao, W.Y., Chen, P.Y., Hsu, H.J., Lin, C.Y., Wu, M.J., and Yen, J.H. (2021). Tanshinone IIA Downregulates Lipogenic Gene Expression and Attenuates Lipid Accumulation Through the Modulation of LXR\u03b1\/SREBP1 Pathway in HepG2 Cells. Biomedicines, 9.","DOI":"10.3390\/biomedicines9030326"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1177\/0300060519859750","article-title":"Tanshinone IIA ameliorates non-alcoholic fatty liver disease through targeting peroxisome proliferator-activated receptor gamma and toll-like receptor 4","volume":"47","author":"Huang","year":"2019","journal-title":"J. Int. Med. Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"9561613","DOI":"10.1155\/2021\/9561613","article-title":"Cinnamic Acid Ameliorates Nonalcoholic Fatty Liver Disease by Suppressing Hepatic Lipogenesis and Promoting Fatty Acid Oxidation","volume":"2021","author":"Wu","year":"2021","journal-title":"Evid.-Based Complement. Altern. Med. Ecam"},{"key":"ref_138","first-page":"5747","article-title":"Unraveling the mechanisms of trans-cinnamic acid in ameliorating non-alcoholic fatty liver disease","volume":"15","author":"Solanki","year":"2023","journal-title":"Am. J. Transl. Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/apt.13981","article-title":"Randomised clinical trial: The efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease","volume":"45","author":"Kim","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3164\/jcbn.21-58","article-title":"Oltipraz ameliorates the progression of steatohepatitis in Nrf2-null mice fed a high-fat diet","volume":"70","author":"Kamisako","year":"2022","journal-title":"J. Clin. Biochem. Nutr."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s40262-024-01420-0","article-title":"Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Firsocostat, a Liver-Targeted Inhibitor of Acetyl-CoA Carboxylase","volume":"63","author":"Weber","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","article-title":"GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease","volume":"155","author":"Loomba","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Sivakumar, P., Saul, M., Robinson, D., King, L.E., and Amin, N.B. (2024). SomaLogic proteomics reveals new biomarkers and provides mechanistic, clinical insights into Acetyl coA Carboxylase (ACC) inhibition in Non-alcoholic Steatohepatitis (NASH). Sci. Rep., 14.","DOI":"10.1038\/s41598-024-67843-8"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41591-021-01489-1","article-title":"ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: Two parallel, placebo-controlled, randomized phase 2a trials","volume":"27","author":"Calle","year":"2021","journal-title":"Nat. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.cmet.2024.01.011","article-title":"DGAT2 inhibition blocks SREBP-1 cleavage and improves hepatic steatosis by increasing phosphatidylethanolamine in the ER","volume":"36","author":"Rong","year":"2024","journal-title":"Cell Metab."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.cmet.2018.04.004","article-title":"DGAT2 Inhibition Alters Aspects of Triglyceride Metabolism in Rodents but Not in Non-human Primates","volume":"27","author":"McLaren","year":"2018","journal-title":"Cell Metab."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"15000","DOI":"10.1021\/acs.jmedchem.2c01200","article-title":"Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-Alcoholic Steatohepatitis","volume":"65","author":"Futatsugi","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e056159","DOI":"10.1136\/bmjopen-2021-056159","article-title":"Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): Rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study","volume":"12","author":"Amin","year":"2022","journal-title":"BMJ Open"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/hep4.1107","article-title":"Role of Aramchol in steatohepatitis and fibrosis in mice","volume":"1","author":"Delgado","year":"2017","journal-title":"Hepatol. Commun."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/brv.12178","article-title":"De novo lipogenesis in the liver in health and disease: More than just a shunting yard for glucose","volume":"91","author":"Sanders","year":"2016","journal-title":"Biol. Rev. Camb. Philos. Soc."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/dom.14272","article-title":"Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials","volume":"23","author":"Beysen","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","article-title":"TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial","volume":"161","author":"Loomba","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2019.10.006","article-title":"Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis","volume":"72","author":"Siddiqui","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"ref_157","first-page":"2050","article-title":"Obeticholic Acid Impact on Quality of Life in Patients with Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a Nonsteroidal FXR Agonist, in Patients with Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/cts.13469","article-title":"Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers","volume":"16","author":"Younis","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00508-020-01735-5","article-title":"Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease","volume":"133","author":"Traussnigg","year":"2021","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2264850","DOI":"10.1080\/07853890.2023.2264850","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid X receptor (FXR) agonist-TQA3526 in healthy Chinese volunteers: A double-blind, randomized, placebo-controlled, dose-escalation, food effect phase I study","volume":"55","author":"Xu","year":"2023","journal-title":"Ann. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2022.10.023","article-title":"Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH","volume":"78","author":"Ratziu","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2021.01.047","article-title":"A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis","volume":"75","author":"Harrison","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: An adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1097\/HEP.0000000000000439","article-title":"Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study","volume":"78","author":"Anstee","year":"2023","journal-title":"Hepatology"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jhep.2020.03.024","article-title":"Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study","volume":"73","author":"Newsome","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S2468-1253(22)00017-6","article-title":"Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): A randomised, double-blind, placebo-controlled, phase 2b trial","volume":"7","author":"Harrison","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients with Nonalcoholic Steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/HEP.0000000000000607","article-title":"A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis","volume":"79","author":"Rinella","year":"2024","journal-title":"Hepatology"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): A multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: A randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/oby.22344","article-title":"Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study","volume":"27","author":"Charles","year":"2019","journal-title":"Obesity"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"106335","DOI":"10.1016\/j.cct.2021.106335","article-title":"The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis","volume":"104","author":"Abdelmalek","year":"2021","journal-title":"Contemp. Clin. Trials"},{"key":"ref_176","first-page":"102","article-title":"Pegbelfermin in Patients with Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study","volume":"22","author":"Loomba","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S2468-1253(22)00347-8","article-title":"Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: A randomised, double-blind, placebo-controlled, phase 1b\/2a multiple-ascending-dose study","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/hep.30590","article-title":"NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis","volume":"71","author":"Harrison","year":"2020","journal-title":"Hepatology"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/hep.32742","article-title":"Fibroblast growth factor receptor 1\/Klotho\u03b2 agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial","volume":"78","author":"Wong","year":"2023","journal-title":"Hepatology"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jhep.2020.09.029","article-title":"Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis","volume":"74","author":"Frenette","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jhep.2019.12.010","article-title":"Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension","volume":"72","author":"Bosch","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jhep.2019.11.024","article-title":"A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis","volume":"72","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/apt.15030","article-title":"Randomised clinical trial: Emricasan versus placebo significantly decreases ALT and caspase 3\/7 activation in subjects with non-alcoholic fatty liver disease","volume":"49","author":"Shiffman","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"ref_187","first-page":"124","article-title":"Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study","volume":"22","author":"Anstee","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"e0335","DOI":"10.1097\/HC9.0000000000000335","article-title":"Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction-associated steatohepatitis","volume":"8","author":"Francque","year":"2024","journal-title":"Hepatol. Commun."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1139\/cjpp-2019-0487","article-title":"Combined treatments with metformin and phosphodiesterase inhibitors alleviate nonalcoholic fatty liver disease in high-fat diet fed rats: A comparative study","volume":"98","author":"Heeba","year":"2020","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_190","first-page":"154368","article-title":"Pentoxifylline attenuates nonalcoholic fatty liver by inhibiting hepatic macrophage polarization to the M1 phenotype","volume":"106","author":"Xu","year":"2022","journal-title":"Phytomedicine Int. J. Phytother. Phytopharm."},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Ye, J.H., Chao, J., Chang, M.L., Peng, W.H., Cheng, H.Y., Liao, J.W., and Pao, L.H. (2016). Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid \u03b2-oxidation. Sci. Rep., 6.","DOI":"10.1038\/srep33102"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/CEJ.0000000000000172","article-title":"Pentoxifylline prevents nonalcoholic steatohepatitis-related liver pre-neoplasms by inhibiting hepatic inflammation and lipogenesis","volume":"25","author":"Shirakami","year":"2016","journal-title":"Eur. J. Cancer Prev. Off. J. Eur. Cancer Prev. Organ. (ECP)"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/hep.25778","article-title":"Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: New evidence on the potential therapeutic mechanism","volume":"56","author":"Zein","year":"2012","journal-title":"Hepatology"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1038\/s41467-023-42162-0","article-title":"ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib\/IIa trial","volume":"14","author":"Hu","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_195","first-page":"106808","article-title":"Dose finding for ZSP1601 in patients with nonalcoholic steatohepatitis using population pharmacokinetics and exposure-response approach","volume":"199","author":"Li","year":"2024","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/apt.17726","article-title":"First in human randomised trial of J2H-1702: A novel 11\u03b2-hydroxysteroid dehydrogenase type 1 inhibitor for non-alcoholic steatohepatitis treatment","volume":"58","author":"Kim","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"5951","DOI":"10.1021\/jm300592r","article-title":"Discovery of a potent, selective, and orally bioavailable acidic 11\u03b2-hydroxysteroid dehydrogenase type 1 (11\u03b2-HSD1) inhibitor: Discovery of 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid (AZD4017)","volume":"55","author":"Scott","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/dom.14646","article-title":"Inhibition of 11\u03b2-Hydroxysteroid dehydrogenase-1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, phase II study","volume":"24","author":"Yadav","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"e001990","DOI":"10.1136\/bmjdrc-2020-001990","article-title":"Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): A randomized prospective open-label controlled trial","volume":"9","author":"Yoneda","year":"2021","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.2337\/dc21-2049","article-title":"Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants with Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial","volume":"45","author":"Takeshita","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"108610","DOI":"10.1016\/j.jdiacomp.2023.108610","article-title":"Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"37","author":"Shi","year":"2023","journal-title":"J. Diabetes Its Complicat."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/dom.15006","article-title":"Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with non-alcoholic fatty liver disease: A prospective randomized study","volume":"25","author":"Hiruma","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep4.1696","article-title":"Ipragliflozin Improves the Hepatic Outcomes of Patients with Diabetes with NAFLD","volume":"6","author":"Takahashi","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-022-01861-9","article-title":"Licogliflozin for nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled, phase 2a study","volume":"28","author":"Harrison","year":"2022","journal-title":"Nat. Med."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1530\/EJE-19-0566","article-title":"Management of Endocrine Disease: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?","volume":"181","author":"Nauck","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1038\/s42255-023-00938-0","article-title":"Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes","volume":"5","author":"Parker","year":"2023","journal-title":"Nat. Metab."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: Randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/hep.31886","article-title":"The Glucagon-Like Peptide-1 Receptor Agonist, Semaglutide, for the Treatment of Nonalcoholic Steatohepatitis","volume":"74","author":"Dichtel","year":"2021","journal-title":"Hepatology"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: Semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jhep.2024.06.003","article-title":"Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon\/glucagon-like peptide-1 receptor dual agonist, in cirrhosis","volume":"81","author":"Lawitz","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"107176","DOI":"10.1016\/j.cct.2023.107176","article-title":"A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis\u2014Study design and rationale of HM-TRIA-201 study","volume":"130","author":"Abdelmalek","year":"2023","journal-title":"Contemp. Clin. Trials"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Lawitz","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_218","doi-asserted-by":"crossref","unstructured":"Grobbee, E.J., de Jong, V.D., Schrieks, I.C., Tushuizen, M.E., Holleboom, A.G., Tardif, J.C., Lincoff, A.M., Schwartz, G.G., Castro Cabezas, M., and Grobbee, D.E. (2022). Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-\u03b1\/\u03b3 agonist aleglitazar. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0277706"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.cgh.2020.10.051","article-title":"A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients with Nonalcoholic Steatohepatitis","volume":"19","author":"Siddiqui","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease","volume":"54","author":"Nakajima","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep4.1657","article-title":"Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH","volume":"5","author":"Harrison","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S2468-1253(21)00300-9","article-title":"Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): A randomised, double-blind, placebo-controlled, phase 2a study","volume":"6","author":"Cusi","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"100474","DOI":"10.1016\/j.xcrm.2021.100474","article-title":"Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study","volume":"2","author":"Fouqueray","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1124\/dmd.122.000953","article-title":"Transporter-Enzyme Interplay in the Pharmacokinetics of PF-06835919, A First-in-Class Ketohexokinase Inhibitor for Metabolic Disorders and Non-Alcoholic Fatty Liver Disease","volume":"50","author":"Weng","year":"2022","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/dom.14946","article-title":"A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes","volume":"25","author":"Saxena","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.medj.2021.04.007","article-title":"Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: A randomized phase 2 trial","volume":"2","author":"Kazierad","year":"2021","journal-title":"Med"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/apt.16664","article-title":"Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis","volume":"54","author":"Safadi","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/cpdd.1179","article-title":"Effect of a High-Fat Meal on Single-Dose Rencofilstat (CRV431) Oral Bioavailability in Healthy Human Subjects","volume":"12","author":"Remenchik","year":"2023","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1002\/hep4.2100","article-title":"Rencofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, single-blind, placebo-controlled study in F2\/F3 NASH","volume":"6","author":"Harrison","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_234","doi-asserted-by":"crossref","unstructured":"Li, H., Liu, N.N., Li, J.R., Dong, B., Wang, M.X., Tan, J.L., Wang, X.K., Jiang, J., Lei, L., and Li, H.Y. (2022). Combined Use of Bicyclol and Berberine Alleviates Mouse Nonalcoholic Fatty Liver Disease. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.843872"},{"key":"ref_235","doi-asserted-by":"crossref","unstructured":"Satyam, S.M., Bairy, L.K., Rehman, A., Attia, M., Ahmed, L., Emad, K., Jaafer, Y., and Bahaaeldin, A. (2024). Unlocking Synergistic Hepatoprotection: Dapagliflozin and Silymarin Combination Therapy Modulates Nuclear Erythroid 2-Related Factor 2\/Heme Oxygenase-1 Pathway in Carbon Tetrachloride-Induced Hepatotoxicity in Wistar Rats. Biology, 13.","DOI":"10.3390\/biology13070473"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.2147\/DDDT.S307257","article-title":"Metformin in Combination with Malvidin Prevents Progression of Non-Alcoholic Fatty Liver Disease via Improving Lipid and Glucose Metabolisms, and Inhibiting Inflammation in Type 2 Diabetes Rats","volume":"15","author":"Zou","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.3748\/wjg.v22.i10.2931","article-title":"Resveratrol and fenofibrate ameliorate fructose-induced nonalcoholic steatohepatitis by modulation of genes expression","volume":"22","author":"Bahgat","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jep.2015.12.004","article-title":"The hepatoprotective effect of the combination use of Fructus Schisandrae with statin\u2014A preclinical evaluation","volume":"178","author":"Wat","year":"2016","journal-title":"J. Ethnopharmacol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"2023-2-10","DOI":"10.7573\/dic.2023-2-10","article-title":"Role of silymarin in the management of deranged liver function in non-alcoholic steatohepatitis: A case report","volume":"12","author":"Lee","year":"2023","journal-title":"Drugs Context"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"2023-1-4","DOI":"10.7573\/dic.2023-1-4","article-title":"Silymarin treatment and reduction of liver enzyme levels in non-alcoholic fatty liver disease: A case report","volume":"12","author":"Chantarojanasiri","year":"2023","journal-title":"Drugs Context"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.2169\/internalmedicine.8754-16","article-title":"The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin","volume":"56","author":"Takeda","year":"2017","journal-title":"Intern. Med."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s13340-020-00448-4","article-title":"Improved insulin sensitivity with sodium-glucose cotransporter 2 inhibitor treatment in a patient with slowly progressive type 1 diabetes mellitus with metabolic syndrome: A case report","volume":"12","author":"Ishizuka","year":"2021","journal-title":"Diabetol. Int."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/1\/140\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:30:17Z","timestamp":1759919417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/1\/140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":242,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["biom15010140"],"URL":"https:\/\/doi.org\/10.3390\/biom15010140","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]}}}